Answers are grounded in this paper and cite their sources.
Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.
No takes yet. Share an insight, caveat, or question.
Bunck et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: